STROKE, cilt.45, sa.8, ss.2372-2378, 2014 (SCI-Expanded)
Background and Purpose-The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate-high stroke risk. Limited data regarding cerebrovascular events with edoxaban were reported previously.